Secretary carcinoma of the breast: A case report

Kamil Pohlodek, Iveta Mečiarová, Petr Grossmann, Petr Martínek, Zdeněk Kinkor

2nd Department of Gynecology and Obstetrics, Faculty of Medicine, Comenius University of Bratislava, Slovakia
Alpha Medical Pathology Ltd., Bratislava, Slovakia
Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Czech Republic
Biologic Laboratory, Ltd., Plzeň, Czech Republic

ABSTRACT

INTRODUCTION: Secretary breast carcinoma (SBC) is a rare breast tumor which accounts for < 0.15% of all breast cancers. It was originally described as a juvenile breast carcinoma, occurring in young children and adolescent women. SBC is associated with a characteristic balanced translocation, t(12;15), that creates ETV6-NTRK3 gene fusion.

PRESENTATION OF CASE: A 52-year-old Caucasian woman had palpable lump in her right breast. After breast imaging examination (BI-RADS 4b) and preoperative core-needle biopsy with suspicion of SBC a breast conserving therapy was performed. The diagnosis of SBC was confirmed through immunohistochemistry and cytogenetic examination of the tumor. The patient is now 22 months post-surgery and remains disease-free.

DISCUSSION: Recent studies reported that the disease occurs at a later age than previously recognized, and is associated with good long-term survival. In breast imaging it may mimic a benign tumor. Immunohistochemistry and cytogenetic analysis of the tumor are crucial for confirmation of SBC.

CONCLUSION: There is no consensus with regard to the best treatment strategy for patients with SBC. Breast conserving therapy with sentinel lymph nodes biopsy is at present the first choice treatment. Further research for a specific NTRK3 tyrosine kinase inhibitor could lead to the discovery of a new targeted treatment of this tumor.

© 2019 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Who has defined the secretary breast carcinoma (SBC) as “a rare, low-grade, translocation-associated invasive carcinoma with a solid, microcystic and tubular architecture composed of cells that produce intracellular and extracellular secretary material “and classed it between “exceptionally rare types and variants” of breast tumors [1]. SBCs account for < 0.15% of all breast cancers [2]. Although it was originally described as a juvenile breast carcinoma, occurring in young children, most cases have been reported in adults of both sexes with the median age of presentation in 25 years [3]. SBC is associated with a characteristic balanced translocation, t(12;15), that creates ETV6-NTRK3 gene fusion [4–6]. Typically, secretary breast carcinomas are negative for hormone receptors and do not express human epidermal growth factor receptor 2 (HER2) [7]. The breast imaging characteristics of SBC are non-specific and can mimic benign breast tumor. A definitive diagnosis of SBC is established from histology, immunohistochemistry and cytogenetic evaluation. We present in our study a patient with SBC in line with the SCARE criteria [8].

2. Case report

A 52-year-old Caucasian woman with no significant previous medical history was referred to the Breast Unit of the 2nd Department of OB/GYN, University Hospital of Bratislava, Slovakia, for assessment of a palpable lump in her right breast. Physical examination revealed a superficial, 1.5-cm lump, located in the lower, inner quadrant of the right breast with clinically negative axillary lymph nodes. Mammography suggested a lobulated, radiopaque 1.5-cm lesion with mostly sharp contours and halo sign (Fig. 1A,B). Breast ultrasonography revealed an round-shaped, low-echoic tumor of unclear etiology (Fig. 1C) with a pathological pattern of blood flow, as seen on Power-Doppler imaging (Fig. 1D). The results of breast imaging examinations were classified as BI-RADS 4b. Infiltrating ductal carcinoma could not be excluded. A ultrasound-guided large-core-needle biopsy was performed and histologic diagnosis of a SBC was supposed. The patient underwent breast conserving surgery with sentinel lymph node biopsy.

Histological evaluation of the surgical specimens showed monoform tumor cells with eosinophilic cytoplasm with vacuoli and...
thyroid-like pseudofollicles, round nuclei with intermediate mitotic activity (MAI 10 MF/10 HPF) (Fig. 2A). The tumor presented with focally infiltrative growth without in situ component. The immunohistochemistry (IHC) showed periodic acid–Schiff (PAS) positive secretory material in intra- and extracellular spaces (Fig. 2B) and negative results for estrogen, progesteron and HER2 receptors. The tumor was positive for cytokeratins 5, 14 and c-Kit protein (CD117) (Fig. 2C,D). There was also diffuse IHC positivity for S100, MUC4, EMA, and scattered positivity for gross cystic disease fluid protein 15. Pan-TRK staining was provided to detect possible neurotrophic tyrosine receptor kinase (NTRK) fusions. Resections margins of more than 10 mm were tumor-free and two sentinel lymph nodes were found to be free of metastases. A dual color break apart probe (SureFISH®, Agilent, St.Clara, USA) was used for fluorescence in situ hybridization (FISH) evaluation of NTRK3 (15q25.3) gene (Fig. 2E). The ETV6-NTRK3 gene fusion was confirmed through FusionPlex® assay kit for solid tumors (ArcherDX, Inc, Colorado, USA). Next generation sequencing (NGS) analysis was used for schematic visualisation of detected fusion transcript ETV6-NTRK3 together with information about the depth of reading of studied area (Fig. 2F).

The post-operative course was uneventful and the patient was discharged home on post-operative day 4. The patient received adjuvant radiation therapy with a total dose of 50 Gy in 26 fractions. She now 22 months post-surgery and remains disease-free.

3. Discussion

SBC has a low-grade clinical course and is associated with a favourable prognosis [3,7,9]. It was originally described in children and adolescent women, with a characteristic morphology and controversy regarding the choice of treatment. Wang et al. [10] referred about a 12-year-old female who presented with SBC in her left breast and underwent breast-conserving therapy without recurrence of the disease. Herz et al. [11] presented case of a 27-year-old woman with pulmonary metastases from a secretary breast cancer treated by mastectomy and axillary lymph node dissection. There was no response to chemotherapy; she died of respiratory failure two and a half years after presentation. Li et al. [12] recently referred about clinical features and treatment of male SBC. A rare occurrence in the ectopic breast tissue of the axilla has been also reported [13].

In mammography, SBC usually presents as a distinctly spiculated lesion or as a discrete, lobulated, solitary mass with smooth or irregular borders, which may mimic a fibroadenoma [7,9]. The
ultrasound findings also mimic benign lesions, demonstrating a well-circumscribed, hypoechoic to isoechoic mass, sometimes with microlobulations [14]. The lesion is usually homogeneous, but it can be heterogeneous [7,11]. In SBC three morphologic patterns are seen in various combinations: microcystic, solid and tubular [1]. The microcystic pattern is composed of small cysts mimicking thyroid follicles. The tubular pattern shows lumina containing secretions. The presence of intra- and extracellular secretory, PAS-positive material (Fig. 2B) is a consistent finding [1–3]. SBCs are in most cases triple negative [3,6,9].

SBC is associated with a characteristic balanced translocation, t(12;15) (p13;q25). This translocation is known to be oncogenic also in another types of neoplasia [4–6]. It affects genes ETV6 (TEL) on the chromosome 12 and NTRK3 (TRKC) on the chromosome 15. The most often it comes to the breakage in the intron 5 of the gene ETV6 and the intron 15 of the gene NTRK3 (Fig. 2F). This creates a fusion gene; or more precisely a protein, where there is N-terminal helix-loop-helix (HLH) domain of the highly expressed transcription factor ETV6 linked to tyrosine kinase domain of the gene NTRK3. The chimeric protein is subject to the ligand dependent HLH mediated dimerization with a subsequent activation of NTRK3 tyrosine kinase domain. The activated tyrosine kinase, then, through a number of signaling pathways, acts in the cell transformation [3,6]. The differential diagnosis with acinic carcinoma is based on the absence of the ETV6-NTRK3 translocation in acinic carcinomas.

Up-to-date, there is no consensus with regard to the best treatment strategy for patients with SBC. At present, surgical excision is the primary therapy for these cases. Axillary metastasis is rare, particularly if the tumor is <2 cm like in this case. Thus, conservative treatment without lymph node examination has been frequently proposed. However, axillary lymph node metastasis has been reported from a 1.5-cm secretory tumor. Involvement of more than three lymph nodes may indicate a risk for distant metastasis and a poor outcome. Therefore, examination of lymph node status using a sentinel lymph node biopsy or axillary lymph node dissection should be performed [9,15]. In general, adjuvant radiation therapy following breast conserving surgery improves loco regional control and disease-specific survival. Although there has been only few reports regarding the effectiveness of radiation therapy in SBC, adjuvant radiation therapy may improve long-term survival as it does for other types of invasive breast cancer. The use of adjuvant chemotherapy has not been thoroughly investigated in SBC, moreover systemic metastasis is rare. Horowitz et al [15] referred in their analysis of SEER data from 83 patients with SBC diagnosed between the years 1983 and 2007 that SBC occurs at a later age than previously recognized, and is associated with good long-term survival.

4. Conclusion

SBC is a rare and indolent type of breast tumor. It presents usually as a palpable breast mass and may resemble a benign lesion using breast imaging. SBCs are slow-growing tumors and generally have a good prognosis. Radiologists should be aware of this rare tumor’s nonspecific imaging features and clinical implications when making a differential diagnosis of solid breast masses. Breast conserving therapy with/without adjuvant chemotherapy is present the standart treatment of SBC. Generally, the tumors are triple negative, so hormonal treatment or targeted anti-HER2 therapies are not considered in most cases. Because of characteristic translocation t(12;15) in SBC, further research for a specific NTRK3 tyrosine kinase inhibitor could lead to the discovery of a new targeted treatment of this tumor [16,17].

Conflicts of interest

The authors herewith disclose no financial and personal relationships with other people or organisations that could inapropriately influence this work.

The authors declare no conflict of interest for writing this manuscript.
Guarantor
Kamil Pohlodek, MD, PhD
Professor of OB/GYN
University Hospital of Bratislava
Corresponding author
on behalf of all co-authors
kamil.pohlodek@fmed.uniba.sk
phone: +421 905 311566

Provenance and peer review
Not commissioned, externally peer reviewed.

References

[1] S.R. Lakhani, I.O. Ellis, S.J. Schnitt, P.H. Tan, M.J. van de Vijver (Eds.), WHO Classification of Tumours of the Breast, 4th edition, IARC, Lyon, 2012, ISBN 978 92 832 2432 7.
[2] P.P. Rosen, M.L. Cranor, Secretory carcinoma of the breast, Arch. Pathol. Lab. Med. 115 (1991) 141–144.
[3] V. Vasudev, K. Onuma, Secretory breast carcinoma: unique, triple-negative carcinoma with favorable prognosis and characteristic molecular expression, Arch. Pathol. Lab. Med. (2011) 1606–1610.
[4] C. Tognon, S.R. Knezevich, D. Huntsman, C.D. Roskelley, N. Melnyk, J.A. Mathiers, L. Becker, F. Carneiro, N. MacPherson, D. Horsman, C. Poremba, P.H. Sorensen, Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma, Cancer Cell 2 (2002) 367–376.
[5] M. Loe, P. Freneaux, X. Sastre-Garau, O. Chouchane, B. Sigal-Zafrani, A. Vincent-Salomon, Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum, Mod. Pathol. 22 (2009) 291–298.
[6] M. Del Castillo, F. Chibon, L. Arnold, S. Croce, A. Ribeiro, G. Perot, J. Hoitstein, S. Geha, C. Bozon, A. Garnier, M. Loe, A. Vincent-Salomon, G. MacGrogan, Secretory breast carcinoma: a histopathologic and genomic spectrum characterized by a joint Specific ETV6-NTRK3 gene fusion, Am. J. Surg. Pathol. 39 (2015) 1458–1467.
[7] D.H. Amott, R. Masters, S. Moore, Secretory carcinoma of the breast, Breast J. 12 (2006) 183.
[8] R.A. Agha, A.J. Fowler, A. Saetta, I. Barai, S. Rajmohan, D.P. Orgill, for the SCARE Group, The SCARE statement: consensus-based surgical case report guidelines, Int. J. Surg. 34 (2016) 180–186.
[9] S.G. Lee, S.P. Jung, H.Y. Lee, S. Kim, H.Y. Kim, I. Kim, J.W. Bae, Secretory breast carcinoma: a report of three cases and a review of the literature, Oncol. Lett. 8 (2014) 683–686.
[10] Y.Q. Wang, Y. Wang, J.H. Zhang, Y.F. Li, H.M. Li, L. Wang, Y. Yao, Secretory breast carcinoma in a 12-year-old girl: a case report, Oncol. Lett. 8 (2014) 1635–1637.
[11] H. Herz, B. Cooke, D. Goldstein, Metastatic secretory breast cancer—nonresponsiveness to chemotherapy: case report and review of the literature, Ann. Oncol. 11 (2000) 1343–1347.
[12] G. Li, X. Zhong, J. Yao, J. Chen, M. Wang, H. Liu, S. Yang, Secretory breast carcinoma in a 41-year-old man with long-term follow-up: a special report, Future Oncol. 11 (2015) 1767–1773.
[13] S.J. Shin, F.S. Shekith, P.A. Allenby, P.P. Rosen, Invasive secretory (juvenile) carcinoma arising in ectopic breast tissue of the axilla, Arch. Pathol. Lab. Med. 125 (10) (2001) 1372–1374.
[14] M.H. Paeng, H.Y. Choi, S.H. Sung, B.J. Moon, S.S. Shim, Secretory carcinoma of the breast, J. Clin. Ultrasound 31 (October (8)) (2003): 425–429.
[15] D.P. Horowitz, C.S. Sharma, E. Connolly, D. Gidea-Addeo, Deutsch I: secretory carcinoma of the breast: results from the survival, epidemiology and end results database, Breast 21 (2012) 350–353.
[16] T.W. Laetsch, S.G. DuBois, L. Mascarenhas, B. Turpin, N. Federman, C.M. Albert, R. Nagasubramanian, J.L. Davis, E. Rudzinski, A.M. Feraco, B.B. Tuch, K.T. Ebata, M. Reynolds, S. Smith, S. Cruickshank, M.C. Cox, A.S. Pappo, D.S. Hawkins, LAROCTENTIN for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase I/2 study, Lancet Oncol. 19 (2018) 705–714.
[17] E. Cocco, M. Scallietti, A. Drilon, NTRK fusion-positive cancers and TRK inhibitor therapy, Nat. Rev. Clin. Oncol. 15 (2018) 731–747.

Open Access
This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.